Lumos Diagnostics (ASX:LDX) Ltd's Rob Sambursky tells Proactive's Andrew Scott the company's expecting to exceed its FY21 prospectus revenue forecast by around 5% as business momentum continues following its listing last month on the ASX. He says it reflects an approximately 200% increase in revenue from FY20 driven by an increase in the number and size of client service contracts and new revenue streams from product manufacturing and product sales.
Lumos Diagnostics expects to beat revenue guidance as strong business momentum continues
